Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $1.3 million.

  • aTYR PHARMA's Share-based Compensation rose 7380.32% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 5844.34%. This contributed to the annual value of $3.0 million for FY2024, which is 1496.15% up from last year.
  • aTYR PHARMA's Share-based Compensation amounted to $1.3 million in Q3 2025, which was up 7380.32% from $1.3 million recorded in Q2 2025.
  • aTYR PHARMA's 5-year Share-based Compensation high stood at $1.3 million for Q3 2025, and its period low was $360000.0 during Q1 2021.
  • Over the past 5 years, aTYR PHARMA's median Share-based Compensation value was $658000.0 (recorded in 2023), while the average stood at $691947.4.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 1489.36% in 2021, then surged by 7950.48% in 2025.
  • Quarter analysis of 5 years shows aTYR PHARMA's Share-based Compensation stood at $414000.0 in 2021, then surged by 46.14% to $605000.0 in 2022, then increased by 8.93% to $659000.0 in 2023, then grew by 16.84% to $770000.0 in 2024, then soared by 69.74% to $1.3 million in 2025.
  • Its Share-based Compensation stands at $1.3 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.2 million for Q1 2025.